Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial
Michael A Matthay1,2, Carolyn S Calfee1,2, Hanjing Zhuo2, B Taylor Thompson3, Jennifer G Wilson4, Joseph E Levitt5, Angela J Rogers5, Jeffrey E Gotts1, Jeanine P Wiener-Kronish6, Ednan K Bajwa3, Michael P Donahoe7, Bryan J McVerry7, Luis A Ortiz8, Matthew Exline9, John W Christman9, Jason Abbott2, Kevin L Delucchi10, Lizette Caballero11, Melanie McMillan11, David H McKenna12
1Department of Medicine and Anesthesia, University of California, San Francisco, CA, USA
2Cardiovascular Research Institute, University of California, San Francisco, CA, USA
3Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
4Department of Emergency Medicine, Stanford University, Stanford, CA, USA
5Department of Medicine, Stanford University, Stanford, CA, USA
6Department of Anesthesiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
7Department of Medicine, University of Pittsburgh, Pittsburgh, Pa. USA
8Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA, USA
9Department of Medicine, Ohio State University Medical Center, Columbus, OH, USA
10Department of Psychiatry, University of California, San Francisco, CA, USA
11Bone and Marrow Transplant Laboratory, University of California, San Francisco, CA, USA
12University of Minnesota, Molecular and Cellular Therapeutics, Saint Paul, MN, USA
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Lancet Respiratory Medicine,The
Tập 7
154-162
Thông tin tác giả